trametinib

Pediatric Long-Term Follow-up and Rollover Study

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Dabrafenib and/or Trametinib Rollover Study

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Pan Tumor Rollover Study

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Molecular Profiling of Advanced Soft-tissue Sarcomas

24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma